233 related articles for article (PubMed ID: 19650075)
1. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
[TBL] [Abstract][Full Text] [Related]
2. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin.
Katsetos CD; Dráberová E; Legido A; Dráber P
J Cell Physiol; 2009 Dec; 221(3):514-20. PubMed ID: 19650077
[TBL] [Abstract][Full Text] [Related]
3. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
Katsetos CD; Draber P; Kavallaris M
Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
[TBL] [Abstract][Full Text] [Related]
4. Class III beta-tubulin in human development and cancer.
Katsetos CD; Herman MM; Mörk SJ
Cell Motil Cytoskeleton; 2003 Jun; 55(2):77-96. PubMed ID: 12740870
[TBL] [Abstract][Full Text] [Related]
5. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
6. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
7. Designer therapies for glioblastoma multiforme.
Sathornsumetee S; Rich JN
Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
[TBL] [Abstract][Full Text] [Related]
8. Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines.
Katsetos CD; Reddy G; Dráberová E; Smejkalová B; Del Valle L; Ashraf Q; Tadevosyan A; Yelin K; Maraziotis T; Mishra OP; Mörk S; Legido A; Nissanov J; Baas PW; de Chadarévian JP; Dráber P
J Neuropathol Exp Neurol; 2006 May; 65(5):465-77. PubMed ID: 16772870
[TBL] [Abstract][Full Text] [Related]
9. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells.
Katsetos CD; Dráberová E; Smejkalová B; Reddy G; Bertrand L; de Chadarévian JP; Legido A; Nissanov J; Baas PW; Dráber P
Neurochem Res; 2007 Aug; 32(8):1387-98. PubMed ID: 17406983
[TBL] [Abstract][Full Text] [Related]
10. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
English DP; Roque DM; Santin AD
Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
[TBL] [Abstract][Full Text] [Related]
11. Emerging microtubule targets in glioma therapy.
Katsetos CD; Reginato MJ; Baas PW; D'Agostino L; Legido A; Tuszyn Ski JA; Dráberová E; Dráber P
Semin Pediatr Neurol; 2015 Mar; 22(1):49-72. PubMed ID: 25976261
[TBL] [Abstract][Full Text] [Related]
12. Beyond grade: molecular pathology of malignant gliomas.
Sulman EP; Guerrero M; Aldape K
Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels.
Pen A; Moreno MJ; Martin J; Stanimirovic DB
Glia; 2007 Apr; 55(6):559-72. PubMed ID: 17266141
[TBL] [Abstract][Full Text] [Related]
14. Brain tumor stem cells as research and treatment targets.
Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
[TBL] [Abstract][Full Text] [Related]
15. Update on tubulin-binding agents.
Attard G; Greystoke A; Kaye S; De Bono J
Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
[TBL] [Abstract][Full Text] [Related]
16. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
17. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
18. 15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest.
Cocca C; Dorado J; Calvo E; López JA; Santos A; Perez-Castillo A
Biochem Pharmacol; 2009 Nov; 78(10):1330-9. PubMed ID: 19576185
[TBL] [Abstract][Full Text] [Related]
19. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
20. βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells.
Bouchet BP; Puisieux A; Galmarini CM
Eur J Cell Biol; 2011 Oct; 90(10):872-8. PubMed ID: 21820201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
